Vaccine against deadly brain cancer shows promise
Key points
- A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly half the patients were alive without their cancer worsening 18 months after diagnosis, the company said on Wednesday.
- The Phase 1 trial involved 16 patients with glioblastoma multiforme, the most common and deadly form of brain cancer.
- They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy.
- "We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr.
A small, early-stage trial of a therapeutic brain cancer vaccine developed by ImmunoCellular Therapeutics Ltd showed that nearly half the patients were alive without their cancer worsening 18 months after diagnosis, the company said on Wednesday.
The Phase 1 trial involved 16 patients with glioblastoma multiforme, the most common and deadly form of brain cancer.
They were treated with ICT-107, an experimental dendritic cell based cancer vaccine, following the standard care of surgery, radiation and chemotherapy.
"We are targeting specific antigens that are on cancer stem cells ... the only population of cells that can really propagate a tumor," said Dr. John Yu, director of surgical neuro-oncology at Cedars-Sinai Medical Center in Los Angeles and ImmunoCellular's chief scientific officer.
A year after diagnosis, all of the patients were alive. After two years, 80% were alive.
Historically, after a year with standard treatment, 61% of glioblastoma patients are alive, and 26.5% are alive after two years, according to the company.
In the ImmunoCellular trial, median overall survival had not yet been reached at the 26.4 months analysis point, with 12 out of 16 patients alive. Seven patients continued to live with no disease progression.
Side effects seen in the trial included fatigue and skin rash.
Dr. Yu said ImmunCellular is planning a mid-stage trial of the vaccine that would include between 30 and 50 patients.
--
By Deena Beasley
LOS ANGELES (Reuters)
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsPhysicians pioneer the use of stereotactic body radiation for deadly kidney cancer complication
UT Southwestern Medical Center Kidney Cancer Program investigators have published what is believed to be the first reported successful use of stereotactic body radiation therapy for an often deadly complication of…
8 April 2015
NewsNew test to predict the effectiveness of cancer vaccines
Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have…
20 February 2015
NewsPTPRZ-MET fusion protein: A new target for personalized brain cancer treatment
Researchers at the University of California, San Diego School of Medicine have identified a new fusion protein found in approximately 15 percent of secondary glioblastomas or brain tumors. The finding offers new…
